China National Pharmaceutical Group: Accounts receivable are expected to increase by the end of 2025.

Securities Daily News: On April 6, Guoyi Yizhi responded to an investor’s question on an interactive platform, stating that regarding accounts receivable, affected by external environmental factors, the accounts receivable collection cycle in the pharmaceutical distribution industry has shown a widespread extension. By the end of 2025, the company’s accounts receivable have also increased. The company places great emphasis on accounts receivable governance, strengthens management of customer creditworthiness, intensifies collection of historical accounts receivable, strictly controls the level of newly added accounts receivable, and reduces accounts receivable risk. Regarding goodwill impairment testing, the company engaged a third-party professional appraisal firm to conduct goodwill and intangible asset impairment assessments for the relevant asset groups. Among them, for the revenue growth rate and gross margin parameters used in the impairment test, the company’s management mainly makes reasonable forecasts about the realization of future profit expectations based on information such as the historical operating conditions of the asset group where the goodwill is located and the development of the industry in which it operates. After analyzing and determining based on historical data and industry conditions, the appraiser adopts these parameters. For the discount rate used in the test, the appraiser determines it based on industry regulatory requirements and appraisal standards. After deducting provisions for goodwill and intangible asset impairment, the net profit attributable to shareholders of the listed company achieved in 2025 increased year over year on a positive basis.

(Edited by Ren Shibi)